Medical news and careers, clearly connected
CareZelo
English
Menu

Ùrachaidhean slàinte poblach

Slàinte phoblachCanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Discontinuation date: Dec 31, 2026 Gach ceann-latha

Faighnich mun gheàrr-chunntas seo

Tha freagairtean air an sgrìobhadh le AI bhon gheàrr-chunntas seo agus dh'fhaodadh iad a bhith ceàrr. Thoir sùil air an tùs thùsail mus dèan thu dad.

2 cheist an-asgaidh gach latha às aonais cunntas. Faodaidh buill faighneachd cho tric 's a thogras iad, an-asgaidh.

Chan e comhairle mheidigeach, laghail no in-imrich a tha seo. Thèid ceistean a chumail gun urra gus ar geàrr-chunntasan a leasachadh.

Leugh an tùs

Tùs oifigeil: Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026 (a' fosgladh ann an taba ùr) — Health Product Shortages Canada

Dèan aithris air duilgheadas

Ri phàigheadh ann an 20 lathaSlàinte phoblachCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Tùs oifigeil: Health Product Shortages Canada (a' fosgladh ann an taba ùr)

Ri phàigheadh ann an 20 lathaSlàinte phoblachCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Tùs oifigeil: Health Product Shortages Canada (a' fosgladh ann an taba ùr)

Ri phàigheadh ann an 39 lathaSlàinte phoblachCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Tùs oifigeil: Health Product Shortages Canada (a' fosgladh ann an taba ùr)

Ri phàigheadh ann an 18 lathaSlàinte phoblachCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Tùs oifigeil: Health Product Shortages Canada (a' fosgladh ann an taba ùr)